Dr. Kimberly V Burke, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 5 Upper Douglas Ln, Oak Bluffs, MA 02557 Phone: 508-687-9320 Fax: 507-684-8457 |
Island Spine Center Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 5 Upper Douglas Ln., Oak Bluffs, MA 02557 Phone: 508-687-9320 Fax: 508-684-8457 |
Martha's Vineyard Chiropractic Center Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2 Ryans Way, Oak Bluffs, MA 02557 Phone: 508-693-4042 Fax: 508-693-4047 |
Island Spine Center Inc. Chiropractor - Independent Medical Examiner Medicare: Not Enrolled in Medicare Practice Location: 5 Upper Douglas Rd., Oak Bluffs, MA 02557 Phone: 508-687-9320 Fax: 508-955-5070 |
Mr. John Donald Campbell, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2 Ryans Way, Oak Bluffs, MA 02557 Phone: 508-693-4042 Fax: 508-696-7256 |
Dr. Karon Hill, D.C. Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 31 Pondview Dr., Oak Bluffs, MA 02557 Phone: 508-693-4654 Fax: 508-693-4654 |
News Archive
According to a new study, children who survive cancer are at a higher risk of cancer later in life or may die early of other cause. The study included almost 900 young cancer survivors treated at Sydney Children's Hospital, from 1972 to 1999, alongside new cancer cases and early deaths. The risk of cancer was five times higher in childhood cancer survivors, the results showed, compared with the overall NSW population, that these survivors were seven and a half times more likely to die early.
There are concerns regarding breast implants and the association with cancer. UP to 30,000 French women and perhaps tens of thousands more around the world may need to have defective breast implants removed after several suspicious cancer cases. The final decision on recall of the implants, produced by the Poly Implant Prothese (PIP) company will be made by the end of the week, after a report from France's National Cancer Institute on December 23.
CSL Behring announced today that it has awarded a $40,000 advocacy grant to the American Plasma Users Coalition (A-PLUS) through its Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations that help people who use plasma-derived or recombinant therapies to manage rare and serious medical disorders.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 4 days ago